Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 20, 2023 16:01 ET
|
Passage Bio
PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
December 14, 2022 07:00 ET
|
Passage Bio
Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in...
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022 07:00 ET
|
Passage Bio
Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to dose the final patient in this phase of the trial by year-endPlan...
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
November 08, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
November 03, 2022 07:30 ET
|
Passage Bio
PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 14, 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
October 10, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 26, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 19, 2022 16:01 ET
|
Passage Bio
PHILADELPHIA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations
August 11, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...